Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials

Documenti analoghi

• Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
  di: Enrica Antonia Martino, et al.
  Pubblicazione: (2025)
• Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
  di: Michèle Hoffmann, et al.
  Pubblicazione: (2025)
• The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
  di: Iuliana Vaxman, et al.
  Pubblicazione: (2026)
• CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
  di: J.T. Jutzi, et al.
  Pubblicazione: (2025)
• Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
  di: Lucio N. Gordan, et al.
  Pubblicazione: (2025)